Biocon Limited has announced the approval of its unaudited condensed consolidated interim financial results for the six months ended September 30, 2025. The results, prepared according to Indian Accounting Standards (Ind AS), were approved by the Board of Directors. Rajesh U. Shanoy, Company Secretary, has confirmed that these results are also posted on the company’s website.
Financial Highlights
Biocon Limited’s board has approved the unaudited condensed consolidated interim financial statements for the period ending September 30, 2025. These results adhere to Indian Accounting Standards (Ind AS) and have been reviewed by the Statutory Auditors, M/s. BSR & Co. LLP.
Key figures from the report include:
- Revenue from operations: ₹82,374 million
- Total Income: ₹84,101 million
- Profit for the period: ₹2,220 million
Segment Performance
The revenue breakdown across different segments is as follows:
- Generics: ₹13,302 million
- Biosimilars: ₹51,471 million
- CRDMO: ₹17,601 million
Key Leadership Commentary
The announcement was formally authorized by key members of Biocon Limited’s leadership, including Kiran Mazumdar-Shaw (Executive Chairperson) and Siddharth Mittal (Managing Director & CEO). These results reflect Biocon’s financial status for the first half of fiscal year 2026.
Source: BSE
